Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 5,000 shares at $3.44 ($17K) on 2026-07-27, disclosed to the SEC on 2026-07-28.
CEO Amit Kumar purchased 5,000 shares for $17,200 on July 27, signaling confidence in the company's oncology pipeline and recent analyst upgrades. This insider buying comes as the stock has rallied significantly over the last 30 days.
The stock is up 27.12% over the past 30 days but remains down 35.58% from its 52-week high of $5.4566, trading at $3.515.
1) Zacks Rank upgrade to Strong Buy on July 22, 2026; 2) Upcoming Phase II breast cancer vaccine study; 3) 2026 described as a 'pivotal year' for CAR-T and vaccine progress.
The stock is currently trading at a forward P/E of -10.26, indicating the company is not yet profitable, and short interest is low at 3.39% of the float.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-09-11 | $14K | — | Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-27 | $11K | — | Filing → |